Michelle Longmire, Medable CEO (Photo Credit: Jeff Rumans)

Med­able trots its way to uni­corn sta­tus amid vir­tu­al tri­al craze. Is a pub­lic de­but next?

As it be­comes ap­par­ent that de­cen­tral­ized clin­i­cal tri­als will like­ly be a part of drug­mak­ers’ strate­gies long af­ter the pan­dem­ic is over, a tech de­vel­op­er is gal­lop­ing its way to uni­corn sta­tus with a $304 mil­lion megaround.

Med­able un­veiled a hefty Se­ries D round on Tues­day — its fourth in the last year and a half — led by Black­stone Growth, Tiger Glob­al and GSR Ven­tures. The new cash brings the Pa­lo Al­to-based com­pa­ny’s to­tal raise to $521 mil­lion, with a whop­ping $2.1 bil­lion val­u­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.